Celon Pharma (FRA:8RP) Loans Receivable: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8RP Celon Pharma SA FRA:8RP
19 GF Score
Price €4.53
GF Value €6.06
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Loans Receivable?

Celon Pharma FRA:8RP -0.55% 19 Loans Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:8RP with a GF Score™ of 19/100 and a GF Value™ of €6.06. The stock has 3 warning signs investors should review.

Celon Pharma's Loans Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Celon Pharma Loans Receivable Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Loans Receivable Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:8RP
19GF Score
Celon Pharma SA FRA:8RP
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
Celon Pharma (FRA:8RP) has a Loans Receivable of €0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Loans Receivable too high?
Celon Pharma's current Loans Receivable is €0.00 Mil. Overall, Celon Pharma has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Loans Receivable compare to ZTS and UTHR?
Celon Pharma's Loans Receivable of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Celon Pharma and its competitors. Celon Pharma's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (FRA:8RP) has a current Loans Receivable of €0.00 Mil. The stock's GF Value™ is €6.06, compared to a current price of €4.53 — trading 25.2% below its estimated fair value. The current Loans Receivable is €0.00 Mil. Celon Pharma's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Celon Pharma (FRA:8RP), the current Loans Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (FRA:8RP) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of €4.53 is trading 25.2% below its estimated GF Value™ of €6.06.

Key valuation signals for FRA:8RP:

  • Loans Receivable: €0.00 Mil
  • GF Value™: €6.06 vs. price of €4.53 (25.2% below fair value)
  • GF Score™: 19/100 with 3 warning signs

No single metric tells the full story. See the FRA:8RP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges CLN:Poland
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
19GF Score

Get the complete analysis for FRA:8RP

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.53
Price
€6.06
GF Value